Vesemnogene lantuparvovec - Lantu Biopharma
Alternative Names: AAV-hSMN1Latest Information Update: 14 Mar 2024
At a glance
- Originator Lantu Biopharma
- Class Gene therapies; Spinal muscular atrophy gene therapies
- Mechanism of Action Gene transference; Survival of motor neuron 1 protein replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Spinal muscular atrophy
Most Recent Events
- 01 Mar 2024 Preclinical trials in Spinal muscular atrophy in China (Parenteral)
- 01 Mar 2024 Lantu Biopharma plans a phase I/II trial for Spinal muscular atrophy (IV) in March 2024 (NCT06288230)